{"disease":{"id":"clostridium-difficile-diarrhea","name":"Clostridium difficile diarrhea","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vancomycin","indication_name":"Clostridium difficile diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01691248","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04305769","title":"Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT01085591","title":"Study of CB-183,315 in Participants With Clostridium Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02218372","title":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT03806803","title":"Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03462459","title":"Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT04003818","title":"Efficacy and Safety of Teicoplanin in CDAD","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT01591863","title":"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT03793686","title":"A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Prolacta Bioscience","has_results":false},{"nct_id":"NCT06839209","title":"Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea","phase":"NA","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"ABResearch S.r.l.","has_results":false},{"nct_id":"NCT03388268","title":"TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03621657","title":"The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT04246151","title":"Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Hamilton Health Sciences Corporation","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}